consolidated financial result fiscal year end december ifrs february company otsuka holdings co ltd stock exchange list tokyo stock exchange code number url httpswwwotsukacoman representative tatsuo higuchi president representative director ceo contact yuji kogure director investor relations department telephone schedule date annual general meeting shareholder march schedule date dividend payment commencement march schedule date security report submission march supplementary material financial result yes earning announcement financial result yes institutional investor analyst press figure round near million state consolidated financial result fiscal year end december consolidated operating result indicate percentage change previous fiscal year profit attributable profit total comprehensive revenue business profit operating profit owner year income year company million yen million yen million yen million yen million yen million yen fy fy reference share profit investment account equity method fy million fy million business profit indicator ordinary earning power calculate follow revenue cost sale sell general administrative expense research development expense share profit investment account equity method application ias income taxis amend result fiscal year end december retrospectively restate dilution basic earning share fiscal year end december return equity basic earning dilute earning ratio profit ratio operate attributable owner share share tax total asset profit revenue company yen yen fy fy consolidated financial position ratio equity equity attributable equity attributable attributable owner total asset total equity owner owner company company company share total asset million yen million yen million yen yen december december application ias income taxis amend figure december retrospectively restate consolidated cash flow net cash flow provide net cash flow net cash flow cash cash equivalent operating activity invest activity financing activity end year million yen million yen million yen million yen fy fy dividend ratio dividend annual dividend share equity dividend attributable second total dividend payout ratio owner quarter quarter quarter yearend total consolidated company end end end consolidated yen yen yen yen yen million yen fy fy fy forecast application ias income taxis amend dividend payout ratio consolidate ratio dividend equity attributable owner company consolidate fiscal year end december retrospectively restate forecast consolidate operating result year end december january december indicate percentage change previous fiscal year profit attributable basic earning revenue business profit operate profit profit year owner share company million yen million yen million yen million yen million yen yen q ytd fy change significant subsidiary fiscal year change specify subsidiary result change scope consolidation change accounting policy change accounting estimate change accounting policy require ifrs yes change accounting policy reason change accounting estimate refer consolidated financial statement major note note consolidated financial statement change accounting policy detail number share issue outstanding common stock number share issue outstanding end fiscal year include treasury share december share december share number share treasury share end fiscal year december share december share average number share outstanding fiscal year fiscal year end december share fiscal year end december share report scope audits external auditor note ensure appropriate use forecast comment particular forecast forwardlooke statement include report base information currently available certain assumption otsuka holdings co ltd hereinafter refer company deem reasonable actual performance result differ significantly factor refer overview operating result financial position forecast consolidated financial result fiscal year end december detail regard assumption matter concern financial forecastthe company plan hold earning release brief institutional investor analyst press february presentation material webcast briefing available company website promptly briefingattachment index overview operating result financial position operating result fiscal year end december research development activity financial position fiscal year end december cash flow fiscal year end december forecast consolidated financial result fiscal year end december basic rationale selection accounting standard consolidate financial statement major note consolidated statement financial position consolidate statement income consolidate statement comprehensive income consolidate statement change equity consolidate statement cash flow note consolidated financial statement note go concern assumption change accounting policy significant accounting estimate judgment operating segment impairment asset earning share business combination subsequent event overview operating result financial position fiscal year end december ias income taxis amend apply comparative analysis previous fiscal year retrospectively restate figure application standard material impact consolidate financial statement detail change accounting policy state note consolidated financial statement change accounting policy consolidate financial statement major note operate result fiscal year end december company affiliate company hereinafter refer group adopt business profit indicator ordinary earning power calculate follow revenue cost sale sell general administrative expense research development expense share profit investment account equity method million yen fy fy fiscal year end fiscal year end change change december december revenue business profit research development expense business profit operate profit profit tax profit year profit attributable owner company research development expense impairment loss base concept total health care group operating business maintain promote health diagnose treat disease anticipate social issue bring highly uncertain world amid change social environment impact geopolitical risk etc group incorporate new technology need arise change environment harness opportunity present grow awareness health order demonstrate group true value total healthcare company continue pursue initiative aim realization sustainable growth revenue fiscal year end december total million previous fiscal year operating segment record increase revenue main factor growth sale global product long act antipsychotic agent abilify maintena antipsychotic agent rexulti vreceptor antagonist jynarque anti cancer agent lonsurf addition growth royalty milestone outlicensed product drive result pharmaceutical business result revenue grew significantly exceed decline revenue expiry exclusive sale period vreceptor antagonist samsca treatment fluid retention patient heart failure hepatic cirrhosis japan furthermore nutraceutical business sale pocari sweat nature continue grow amid increase health awareness business profit research development expense million main factor follow hand gross profit increase high sale global product increase royalty milestone license product hand amid effort accelerate investment new business sga expense ratio reduce appropriately control sell general administrative expense efficient investment exist business research development expense total million mainly development expense base collaboration license agreement execute sumitomo pharma co ltd joint development commercialization relate antipsychotic agent novel mechanism action steady progress zipalertinibta development treatment nonsmall cell lung cancer sibeprenlimabvis development treatment iga nephropathy impact exchange rate fluctuation result great anticipate sale growth appropriate control impose sell general administrative expense business profit increase significantly million operating profit decrease million main factor impact record total million impairment loss fiscal year end december impairment loss avp drug agitation associate dementia alzheimer disease fourth quarter fiscal year addition impairment loss product pertain daiya foods inc collaboration sumitomo pharma co ltd record quarter fiscal year profit year million profit attributable owner company million result business segment follow million yen consumer pharmaceutical nutraceutical adjustment total product revenue business profit reference fy million yen consumer pharmaceutical nutraceutical adjustment total product revenue business profit pharmaceutical revenue pharmaceutical business fiscal year end december total million business profit million main product global product group position long act antipsychotic agent abilify maintena antipsychotic agent rexultirxulti vreceptor antagonist samscajinarcjynarque anticancer agent lonsurf global product sale product total million brand antipsychotic agent outside europe brand antipsychotic agent europe brand autosomal dominant polycystic kidney disease adpkd treatment multiple region outside japan brand adpkd treatment long act antipsychotic agent abilify maintena sale increase atop growth prescription mainly promote efficacy product bipolar disorder schizophrenia patient problem adhere drug regimen facetoface detail activity impact exchange rate fluctuation japan sale grow steadily strong information provision activity bipolar disorder addition schizophrenia result sale abilify maintena total million antipsychotic agent rexultirxulti drug sell adjunctive therapy major depressive disorder treatment schizophrenia treatment agitation associate dementia alzheimer disease group actively engage activity raise awareness agitation associate dementia alzheimer disease conduct dtc advertising prescription grow sale increase mainly enhancement facetoface detail activity impact exchange rate fluctuation japan sale increase boost new prescription enhancement detail activity schizophrenia result sale rexultirxulti total million direct consumer vreceptor antagonist samsca japan number prescription autosomal dominant polycystic kidney disease adpkd increase number patient receive treatment exceed case hand sale significantly decrease impact launch generic treatment fluid retention patient heart failure hepatic cirrhosis drug sell treatment hyponatremia sale significantly decrease impact launch generic result sale samsca total million vreceptor antagonist jinarcjynarque sale increase significantly result increase number prescription adpkd mainly continue effort raise awareness disease provision information clinical datum impact exchange rate fluctuation result sale jinarcjynarque total million anticancer agent lonsurf sale increase significantly approval august additional indication treatment combination bevacizumab colorectal cancer recommendation combination therapy nccn guidelines impact exchange rate fluctuation europe sale increase increase number prescription impact exchange rate fluctuation addition combination therapy approve july japan sale continue solid increase awareness combination therapy follow publication research paper etc result sale lonsurf total million cancer treatment guideline widely world nutraceutical revenue nutraceutical business fiscal year end december total million business profit million main product group position pocari sweat nature nutrition sant sas brand major brand sale brand total million total sale nurture brand daiya foods inc brand equelle body maint million major brand sale volume pocari sweat electrolyte supplement drink decrease temporarily impact price revision april japan sale volume increase summer year high temperature record promotion consumption accompany rise interest measure heat disorder daily life increase brand contact point drinking experience sport event hot spa facility factor include continue education hydration replenishment electrolyte overseas people recognize importance hydration replenishment electrolyte activity raise awareness tailor culture situation region build brand image year initiative sale volume increase result sale volume increase overall brand lead increase sale sale nature supplement pharmavite llc increase expand market share back high trust brand quality boost marketing activity social medium impact exchange rate fluctuation nutrition sant sas brand sell health food product mainly europe expand food service ecommerce sale decline impact business reorganization japanese yenbased sale increase mainly growth main product gerbl impact exchange rate fluctuation japan meteorological agency average temperature summer june august japan high recordkeeping begin iri datum market advantage calendar ytd food drug mass exclude amazon costco service provide meal public institution school etc nurture brand plantbase food daiya foods inc brand see decrease sale mainly increase competition dairy alternative cheese market north america effort enhance product lineup utilize original technology expand distribution sale equelle food supplement brand contain equol support women health beauty grow japan increase recognition product wideranging spread information product include seminar women health steady increase number ecommerce subscription body maint protective beverage brand contain plantbase lacticacid bacteria b sale decline december new communication campaign start propose manage one physical condition daily basis preparation important day effort develop core user raise recognition increase consumption product lactiplantibacillus pentosus onricb strain isolate tokyo university agriculture otsuka pharmaceutical confirm efficacy consumer product revenue consumer product business fiscal year end december total million business profit total million increase share profit associate mineral water product sale mainstay brand crystal geyser remain par previous fiscal year japan mainly appeal brand value communicate environmental initiative use lightweight bottle cap bottle recycled raw material sale volume decrease impact price revision sale volume match carbonate vitamin drink increase increase number user exist product strong sale match salty lemon soda launch march match vitamin mikan launch october revenue fiscal year end december total million business profit million sale specialty chemical business remain par previous fiscal year despite delay recovery semiconductor market stagnation chinese market sale fine chemical business increase mainly increase sale antibiotic intermediate transportation warehousing business despite acquisition new external customer steady growth handle volume strengthen total healthcare distribution platform coordination logistic data sale decrease marginally decline unit freight rate international transportation refer supplement document fact book sale product information httpswwwotsukacomenirlibrarymaterialshtml research development activity research development expense fiscal year end december total million primary area research development status new product development segment follow pharmaceutical group conduct research development primary focus area psychiatry neurology oncology group conduct research development focus field fully address cardiovascular renal system etc research development expense pharmaceutical business fiscal year end december million research development activity pharmaceutical business carry fiscal year end december summarize development treatment category brand generic area status code indication psychiatry opc rexulti brexpiprazole japan major depressive grant approval rxulti disorder additional indication neurology december japan agitation associate application file dementia approval alzheimer disease additional indication october agitation associate grant approval dementia additional indication alzheimer disease europe major depressive discontinued business disorder reason agitation associate discontinued business dementia reason alzheimer disease aripiprazole long abilify aripiprazole china schizophrenia grant approval act injection maintena aripiprazole abilify schizophrenia grant approval april month long asimtufii bipolar disorder acting injection avp deuterium negative symptom discontinue strategic modify schizophrenia reason dextromethorphan quinidine sep japan bipolar depression discontinue study significant delay recruitment progress oncology astx inaqovi decitabine europe myelodysplastic application file cedazuridine syndrome approval additional indication december china myelodysplastic phase iii trial syndrome initiate october europe acute myeloid grant approval leukemia september astx tolinapant solid tumor discontinue strategic lymphoma reason astx tolinapant tcell lymphoma phase trial initiate astx decitabine february cedazuridine acute myeloid discontinue strategic leukemia reason ap iclusig ponatinib china chronic myeloid application file leukemia acute march lymphoblastic leukemia ta jeselhy pimitespib japan prostate cancer phase ii trial initiate september development treatment category brand generic area status code indication oncology ta lytgobi futibatinib japan unresectable biliary grant approval june tract cancer harbor fgfr gene fusion progress chemotherapy europe cholangiocarci grant approval july noma tas japan nonsmall cell lung phase iii trial cancer initiate june europe ta prostate cancer discontinue strategic reason europe ta zipalertinib japan nonsmall cell lung phase iii trial initiate cancer december europe ab zimberelimab japan upper phase iii trial initiate ab domvanalimab gastrointestinal tract june cancer japan nonsmall cell lung phase trial initiate cancer june ab zimberelimab japan solid tumor phase trial initiate ta futibatinib january opfc zinc chloride japan cancerous skin phase ii trial initiate ulcer july opb japan solid tumor discontinue strategic reason cardio opc samtasu tolvaptan sodium china cardiac edema application file vascular phosphate december renal voclosporin japan lupus nephritis application file system november etc bempedoic acid japan hyper phase iii trial initiate cholesterolemia february opc japan cardiac edema phase ii trial initiate january opf japan highcalorie application file category parenteral nutrition chronic renal failure opa moizerto difamilast china atopic dermatitis phase iii trial initiate february opcel mikeluna carteolol china glaucoma ocular phase iii trial initiate latanoprost hypertension op china irritable bowel phase ii trial initiate syndrome june vis tbd autoimmune disease phase trial initiate january description status europe application file indicate application approval submit accept relevant authority country region indicate application approval submit relevant authority nutraceutical nutraceutical business group draw knowledge pharmaceutical business conduct research development scientifically base original product order maintain promote health people october skin care brand innersignal release innersignal sc rich cream beauty cream develop focus stratification stratum corneum research development expense nutraceutical business fiscal year end december million outermost skin layer cellular turnover take place facial skin layer play important role moisture retention protective barrier function consumer product consumer product business group engage research development original unique product field food beverage everyone daily life group create propose innovative product base theme food health target business retort food beverage plantbase food aim solve issue associate change society involve health environment population age society research development expense consumer product business fiscal year end december million business group primarily engage research development specialty chemical product fine chemical group focus organic inorganic synthesis technology conduct research development new product center technology nextgeneration field research development expense business fiscal year end december million financial position fiscal year end december million yen change december december current asset noncurrent asset total asset current liability noncurrent liability total liability total equity asset total asset december million increase million compare million december current asset increase million noncurrent asset increase million current asset current asset december million increase million compare million december mainly increase cash cash equivalent million trade receivable million inventory million income taxis receivable million noncurrent asset noncurrent asset december million increase million compare million december mainly increase property plant equipment million goodwill million investment account equity method million financial asset million defer tax asset million partially offset decrease intangible asset million intangible asset decrease mainly recording total million impairment loss include related avp development treatment agitation associate dementia alzheimer disease daiya foods inc collaboration sumitomo pharma co ltd asset increase overall result depreciation yen addition impact exchange rate fluctuation increase property plant equipment capital investment increase goodwill trademark distribution right acquisition bonafide health llc bonafide health increase defer tax asset increase elimination unrealize gain inventory tax effect impairment loss intangible asset b liability total liability december million increase million compare million december current liability increase million noncurrent liability decrease million current liability current liability december million increase million compare million december mainly increase trade payable million bond borrowing million income taxis payable million current liability million increase bond borrowing reclassification currentportion bond current liability noncurrent liability noncurrent liability december million decrease million compare million december mainly decrease bond borrowing million financial liability million c equity total equity december million increase million compare million december mainly increase retain earning million consist profit attributable owner company million net dividend payment million increase component equity million result depreciation yen cash flow fiscal year end december cash cash equivalent december million increase million compare balance december fiscal year end december net cash flow provide operating activity million net cash flow investing activity million result capital investment pharmaceutical business nutraceutical business sustainable growth acquisition bonafide health nutraceutical business net cash flow financing activity million result repayment borrowing lease liability million dividend pay cash cash equivalent increase million operate cash inflow exceed total investing financing cash outflow follow provide detail cash flow movement fiscal year end december cash flow operating activity net cash flow provide operating activity million increase million compare previous fiscal year cash flow provide operating activity fiscal year end december mainly consist million profit tax adjust million depreciation amortization expense million impairment loss reversal impairment losse million increase trade receivables million income taxis pay cash inflow operating activity increase million previous fiscal year despite decrease profit tax recording impairment loss relate avp daiya foods inc collaboration sumitomo pharma co ltd million increase outflow income taxis pay large growth royalty milestone global product outlicense product pharmaceutical business drive business performance contribute significantly increase cash flow operating activity cash flow invest activity net cash flow investing activity million increase outflow million compare previous fiscal year cash flow investing activity fiscal year end december mainly consist million payment acquisition property plant equipment million payment acquisition intangible asset million payment acquisition subsidiary bonafide health company specialize creation sale product women health increase million outflow primarily million increase payment acquisition property plant equipment million increase payment acquisition subsidiary cash flow financing activity net cash flow financing activity million decrease outflow million compare previous fiscal year cash flow financing activity fiscal year end december mainly consist million net increase shortterm borrowing million repayment longterm borrowing million repayment lease liability million dividend pay forecast consolidated financial result fiscal year end december financial forecast fiscal year end december follow million yen fy actual fy forecast change change revenue business profit research development expense business profit operate profit profit tax profit year profit attributable owner company research development expense note fy project exchange rate yenusd yeneur pharmaceutical business revenue expect increase result strongly drive growth royalty income global product abilify maintena rexultirxulti jinarcjynarque lonsurf outlicense product nutraceutical business revenue expect increase growth sale major brand pocari sweat nature nutrition sant sas brand nurture brand daiya foods inc brand equelle body maint sell general administrative expense group engage growth investment involve large new business challenge new frontier group promote cost adjustment exist business research development expense group expect invest sibeprenlimabvi development treatment iga nephropathy avp development treatment agitation associate dementia alzheimer disease tas development treatment nonsmall cell lung cancer view achieve sustainable growth business profit expect high fiscal year end december sale global product nutraceutical business expect increase cost adjustment exist business promote despite promotion investment new business operate profit expect increase record substantial impairment loss year fiscal year end december company project consolidate revenue million current fiscal year business profit research development expense million business profit million operating profit million profit tax million profit year million profit attributable owner company million basic rationale selection accounting standard group adopt international financial reporting standard ifrs enhance international comparability financial report consolidated financial statement major note consolidated statement financial position million yen december december asset current asset cash cash equivalent trade receivables inventory income taxis receivable financial asset current asset subtotal asset hold sale total current asset noncurrent asset property plant equipment goodwill intangible asset investment account equity method financial asset defer tax asset noncurrent asset total noncurrent asset total asset million yen december december liabilities equity liability current liability trade payable bond borrowings lease liability financial liability income taxis payable provision contract liability current liability total current liability noncurrent liability bond borrowing lease liability financial liability net define benefit liability provision contract liability defer tax liability noncurrent liability total noncurrent liability total liability equity equity attributable owner company share capital capital surplus treasury share retain earning component equity total equity attributable owner company noncontrolle interest total equity total liability equity consolidate statement income million yen fy fy january january december december revenue cost sale gross profit sell general administrative expense share profit investment account equity method research development expense impairment loss income expense operate profit finance income finance expense profit tax income tax expense profit year attributable owner company noncontrolle interest profit period earning share basic earning share yen dilute earning share yen consolidate statement comprehensive income million yen fy fy january january december december profit year comprehensive income item reclassify profit loss remeasurement define benefit plan financial asset measure fair value comprehensive income share comprehensive income investment account equity method subtotal item reclassified profit loss exchange difference translation foreign operation cash flow hedge share comprehensive income investment account equity method subtotal total comprehensive income total comprehensive income year attributable owner company noncontrolle interest total comprehensive income year consolidate statement change equity fy january december millions yen equity attributable owner company component equity financial asset treasury retain measure fair share capital capital surplus remeasurement share earning value define benefit plan comprehen sive income balance january cumulative effect change accounting policy restate balance profit year comprehensive income comprehensive income year purchase treasury share dividend sharebase payment transaction change ownership interest subsidiary result loss control transfer component equity retain earning total transaction owner balance december equity attributable owner company component equity noncontrolle exchange total equity interest difference total cash flow translation total hedge foreign operation balance january cumulative effect change accounting policy restate balance profit year comprehensive income comprehensive income year purchase treasury share dividend sharebase payment transaction change ownership interest subsidiary result loss control transfer component equity retain earning total transaction owner balance december fy january december millions yen equity attributable owner company component equity financial asset treasury retained measure fair share capital capital surplus remeasurement share earning value define benefit plan comprehen sive income balance january profit year comprehensive income comprehensive income year purchase treasury share dividend sharebase payment transaction change ownership interest subsidiary result loss control transfer component equity retain earning total transaction owner balance december equity attributable owner company component equity noncontrolle exchange total equity interest difference total cash flow translation total hedge foreign operation balance january profit year comprehensive income comprehensive income year purchase treasury share dividend sharebase payment transaction change ownership interest subsidiary result loss control transfer component equity retain earning total transaction owner balance december consolidate statement cash flow million yen fy fy january january december december cash flow operating activity profit tax depreciation amortization expense impairment loss reversal impairment loss share profit investment account equity method finance income finance expense increase inventory increase trade receivables increase decrease trade payable subtotal interest dividend receive interest pay income taxis pay net cash flow provide operating activity cash flow invest activity proceed sale property plant equipment payment acquisition property plant equipment payment acquisition intangible asset proceed sale redemption investment payment acquisition investment proceed sale subsidiary payment acquisition subsidiary increase decrease time deposit net cash flow investing activity cash flow financing activity purchase treasury share change shortterm borrowing net proceed longterm borrowing repayment longterm borrowing repayment lease liability dividend pay capital contribution noncontrolle interest payment acquisition interest subsidiary noncontrolle interest net cash flow financing activity increase cash cash equivalent cash cash equivalent begin year effect exchange rate change cash cash equivalent cash cash equivalent end year note consolidated financial statement note go concern assumption applicable change accounting policy group apply ias income taxis amend fiscal year end december ifrs description new standard interpretation amendment clarification accounting treatment defer taxis relate asset liability ia income taxis arise single transaction application standard clarifie accounting treatment initial recognition transaction rise equal taxable deductible temporary difference time transaction result recognition taxable deductible temporary difference defer tax liability asset respectively consolidate statement financial position result application standard previous fiscal year consolidated financial statement retrospectively restate effect application decrease defer tax asset million increase defer tax liability million decrease total equity million consist decrease retain earning million component equity million noncontrolling interest million consolidate statement financial position december addition effect increase income tax expense million decrease profit year million consolidate statement income fiscal year end december cumulative effect application standard beginning balance retain earning fiscal year end december decrease million consolidated statement change equity significant accounting estimate judgment prepare ifrscompliant consolidated financial statement management require judgment estimate assumption affect application accounting policy report amount asset liability revenue expense actual result differ estimate estimate underlying assumption review ongoing basis effect review accounting estimate recognize accounting period review conduct future accounting period item significant effect amount recognize consolidated financial statement follow impairment intangible asset fair value measurement financial instrument recoverability defer tax asset measurement define benefit obligation estimation statutory contractual rebate relate public health system operate segment overview reportable segment group reportable segment constituent unit group separate financial information available subject periodic review board director order decision allocation business resource evaluate business performance respective segment company hold company direct group strategic planning decisionmake monitor group operation provide common service group company business activity conduct group subsidiary associate center healthcare business group operate activity inside outside japan relate follow reportable segment pharmaceutical nutraceutical consumer product business group define reportable segment follow pharmaceutical comprise manufacture sale prescription drug intravenous solution nutraceutical comprise manufacture sale functional beverage overthecounter drug nutritional supplement consumer product comprise manufacture sale mineral water soft beverage food product encompass logistic warehousing manufacturing sale chemical evaluation system lead display spectroanalysis device revenue performance reportable segment segment profit base operate profit intersegment revenue transfer reflect reasonable price intersegment transfer base market value revenue performance group reportable segment follow fy january december millions yen reportable segment adjustment consolidated pharma nutra consumer total ceutical ceutical product revenue revenue external customer intersegment revenue transfer total segment profit item depreciation amortization expense share profit loss investment account equity method impairment loss capital expenditure fy january december millions yen reportable segment adjustment consolidated pharma nutra consumer total ceutical ceutical product revenue revenue external customer intersegment revenue transfer total segment profit item depreciation amortization expense share profit loss investment account equity method impairment loss capital expenditure detail adjustment follow segment profit follow table show segment profit adjustment million yen fy fy january january december december intersegment elimination unallocated expense income total unallocated expense incur administrative department headquarters company certain subsidiary item depreciation amortization expense impairment loss adjustment include depreciation amortization expense impairment loss property plant equipment intangible asset asset associate headquarters function company certain subsidiary capital expenditure adjustment include capital expenditure relate asset associate headquarters research function company certain subsidiary capital expenditure purchase property plant equipment goodwill intangible asset impairment asset fy fiscal year end december group record impairment loss million fiscal year end december million relate pharmaceutical business pharmaceutical business group receive complete response letter crl food drug administration fda vadadustat treatment anemia prior dialysis phase indicate application ready approval present form result impairment loss million record carrying amount inprocess research development recognize intangible asset relate asset reduce zero fy fiscal year end december group record impairment loss million fiscal year end december million relate pharmaceutical business million relate nutraceutical business pharmaceutical business main impairment loss million impairment loss avp development treatment agitation associate dementia alzheimer disease million impairment loss relate intangible asset record base collaboration license agreement execute sumitomo pharma co ltd joint development commercialization concern avp group receive result phase iii clinical study study target agitation associate dementia alzheimer disease indicate study meet primary endpoint delay initially anticipate approval application timeline diminish probability market approval group reevaluate intangible asset process research development result impairment loss million record carrying intangible asset reduce recoverable value use calculation value use discount rate base pretax weight average cost capital group receive result clinical study relate intangible asset record base collaboration license agreement execute sumitomo pharma co ltd joint development commercialization indicate diamond diamond clinical study phase iii evaluate ulotaront acutely psychotic adult schizophrenia meet primary endpoint confirm delay initially anticipate approval application timeline group reevaluate intangible asset inprocess research development result impairment loss million record carrying intangible asset reduce recoverable value use calculation value use discount rate base pretax weight average cost capital nutraceutical business profitability daiya foods inc develop manufacture sell plantbase food north america decline result increase competition dairy alternative cheese market north america accordingly group reduce carry asset relate daiya food inc recoverable amount record impairment loss million million goodwill million trademark distribution right million intangible asset recoverable amount measure fair value cost disposal fair value cost disposal measure primarily take account analysis income approach calculate discount estimate future cash flow year base business plan reflect past experience external information approve management discount rate calculate pretax weight average cost capital project period business plan subsequent growth rate estimate hierarchy fair value level earning share basis calculate basic earning share fy fy january january december december profit attributable owner company million yen attributable ordinary equity holder company million yen profit calculation basic earning share millions yen weight average number ordinary share thousand share basic earning share yen basis calculate dilute earning share fy fy january january december december profit calculation basic earning share million yen adjustment profit year million yen profit calculation dilute earning share millions yen weight average number ordinary share thousand share increase ordinary share weight average number dilute ordinary share thousand share dilute earning share yen dilution earning share fy business combination significant business combination acquisition bonafide health llc pharmavite llc pharmavite consolidated subsidiary company enter agreement acquire share bonafide health llc bonafide health company specialize creation sale product women health acquisition complete november outline business combination acquire company business description acquire company bonafide health llc business description manufacture sale supplement medical device primarily aim womens health ii main reason business combination bonafide health found mission contribute womens health provide innovative safe effective choice company engage research develop marketing new natureinspired health product woman product bonafide health ground science endorse healthcare professional company address complex health need woman evolve age offer longterm sustain support acquisition bonafide health pharmavite expand exist portfolio women health field comprise uqora novel urinary tract health brand equelle supplement equol iii date obtain control november iv method obtain control acquire company percentage equity voting right acquire pharmavite consolidated subsidiary company acquire share voting right bonafide health cash consideration fair value consideration pay asset acquire liability assume date control obtain millions yen fair value consideration pay cash fair value asset acquire liability assume current asset noncurrent asset current liability noncurrent liability fair value asset acquire liability assume goodwill direct cost acquisition million include sell general administrative expense consolidate statement income acquire trade receivable contractual cash flow expect collect goodwill consist mainly synergie exist business excess earning power expect arise acquisition goodwill expect deductible tax purpose major component noncurrent asset allocate intangible asset million trademark distribution right million intangible asset impact group financial result revenue profit loss include group consolidate statement income arise bonafide health date acquisition control immaterial disclosure revenue profit loss assume date business combination january socalle pro forma information omit impact immaterial contingent consideration contingent consideration record result business combination involve neurovance inc recor medical inc etc contingent consideration acquisition neurovance inc consist milestone pay base progress development centanafadine compound development treatment adhd obtain group acquire neurovance inc march one pay base revenue launch centanafadine maximum potential amount milestone usd million usd million respectively contingent consideration milestone base development progress ultrasound renal denervation device acquire business combination recor medical inc june settle december fair value contingent consideration estimate base probabilityweighte present value potential pay counterparty fair value change contingent consideration attributable time value recognize finance expense attributable change nontimevalue recognize income expense change fair value contingent consideration follow million yen balance december change fair value foreign currency translation adjustment balance december change fair value settlement period foreign currency translation adjustment balance december subsequent event applicable